(S)-N-(tert-butoxycarbonyl)-3,4-(methylenedioxy)phenylglycine | 1241683-90-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-N-(tert-butoxycarbonyl)-3,4-(methylenedioxy)phenylglycine
• 英文别名: (S)-2-(benzo[d][1,3]dioxol-5-yl)-2-((tert-butoxycarbonyl)amino)acetic acid；(2S)-2-(1,3-benzodioxol-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid
• CAS: 1241683-90-8
• 化学式: C₁₄H₁₇NO₆
• 分子量: 295.292
• InChiKey: QMSQSZSULCZBGT-NSHDSACASA-N

物化性质

• 沸点：
  467.6±45.0 °C(Predicted)
• 密度：
  1.320±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  94.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-N-(tert-butoxycarbonyl)-3,4-(methylenedioxy)phenylglycine 在 盐酸 、 氯甲酸乙酯 、 三乙胺 作用下， 以 硝基甲烷 为溶剂， 反应 4.0h， 生成 (6R,7R)-7-((S)-2-Amino-2-benzo[1,3]dioxol-5-yl-acetylamino)-3-methyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  参考文献：
  名称：

  Orally active cephalosporins and penicillins

  摘要：

  A number of orally active cephalosporins and penicillins with interesting biological activity were synthesized. Two of these, 7-[[[3,4-(methylenedioxy)phenyl]glycyl]amino]deacetoxycephalosporanic acid and 7-[[2-(2,3-dihydro-5-benzofuranyl)glycyl]amino]deacetoxycephalosporanic acid were considerably more active than cephalexin both in vitro and in vivo against staphylococcal and streptococcal infections.

  DOI：

  10.1021/jm00178a011
• 作为产物：
  描述：

  N-重氮基氨基甲酸叔-丁基酯 、 (S)-(+)-3,4-(methylenedioxy)phenylglycine 在 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 30.0h， 生成 (S)-N-(tert-butoxycarbonyl)-3,4-(methylenedioxy)phenylglycine
  参考文献：
  名称：

  Orally active cephalosporins and penicillins

  摘要：

  A number of orally active cephalosporins and penicillins with interesting biological activity were synthesized. Two of these, 7-[[[3,4-(methylenedioxy)phenyl]glycyl]amino]deacetoxycephalosporanic acid and 7-[[2-(2,3-dihydro-5-benzofuranyl)glycyl]amino]deacetoxycephalosporanic acid were considerably more active than cephalexin both in vitro and in vivo against staphylococcal and streptococcal infections.

  DOI：

  10.1021/jm00178a011

文献信息

• <i>N</i>‐Boc‐Protected α‐Amino Acids by 1,3‐Migratory Nitrene C(sp³)−H Insertion
  作者：Bing Zhou、Chen‐Xi Ye、Eric Meggers

  DOI：10.1002/ejoc.202300296

  日期：2023.7.8

  N‐Boc‐protected α‐amino acids are synthesized in two steps from linear or branched carboxylic acid feedstocks. In the first step, the carboxylic acid is coupled with tert‐butyl aminocarbonate (BocNHOH) to generate azanyl ester (acyloxycarbamate) RCO₂NHBoc. In the second step, this azanyl ester undergoes a stereocontrolled iron‐catalyzed 1,3‐nitrogen migration to generate the N‐Boc‐protected non‐racemic α‐amino acid. This straightforward protocol is applicable to the catalytic asymmetric synthesis of α‐monosubstituted α‐amino acids with aryl, alkenyl, and alkyl side chains. Furthermore, α,α‐disubstituted α‐amino acids are accessible in an enantioconvergent fashion from racemic carboxylic acids. The new method is also advantageous for the synthesis of α‐deuterated α‐amino acids. N‐Boc‐protected α‐amino acids synthesized using this two‐step protocol are ready‐to‐use building blocks.

  摘要N-叔丁氧羰基保护的α-氨基酸由线性或支链羧酸原料分两步合成。第一步，羧酸与氨基甲酸叔丁酯（BocNHOH）偶联生成偶氮酯（酰氧基氨基甲酸酯）RCO2NHBoc。在第二步中，该氮杂环戊烯酯经过立体控制的铁催化 1,3 氮迁移，生成 N-Boc 保护的非亲和 α-氨基酸。这种直接的方案适用于催化不对称合成带有芳基、烯基和烷基侧链的 α-单取代 α-氨基酸。此外，α,α-二取代的α-氨基酸可以从外消旋羧酸中以对映转化的方式获得。这种新方法还有利于合成α-氚代α-氨基酸。采用这种两步法合成的 N-Boc 保护的 α- 氨基酸是即用型构筑模块。
• US4020060A
  申请人：——

  公开号：US4020060A

  公开（公告）日：1977-04-26
• Orally active cephalosporins and penicillins
  作者：E. H. W. Boehme、R. E. Bambury、R. J. Baumann、R. C. Erickson、B. L. Harrison、P. F. Hoffman、F. J. McCarty、R. A. Schnettler、M. J. Vaal、D. L. Wenstrup

  DOI：10.1021/jm00178a011

  日期：1980.4

  A number of orally active cephalosporins and penicillins with interesting biological activity were synthesized. Two of these, 7-[[[3,4-(methylenedioxy)phenyl]glycyl]amino]deacetoxycephalosporanic acid and 7-[[2-(2,3-dihydro-5-benzofuranyl)glycyl]amino]deacetoxycephalosporanic acid were considerably more active than cephalexin both in vitro and in vivo against staphylococcal and streptococcal infections.